DK0786255T3 - Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein - Google Patents

Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein

Info

Publication number
DK0786255T3
DK0786255T3 DK96117245T DK96117245T DK0786255T3 DK 0786255 T3 DK0786255 T3 DK 0786255T3 DK 96117245 T DK96117245 T DK 96117245T DK 96117245 T DK96117245 T DK 96117245T DK 0786255 T3 DK0786255 T3 DK 0786255T3
Authority
DK
Denmark
Prior art keywords
lfa
administering
allotransplants
xenografts
binding protein
Prior art date
Application number
DK96117245T
Other languages
Danish (da)
English (en)
Inventor
Barbara Wallner
Christopher Benjamin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DK0786255T3 publication Critical patent/DK0786255T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96117245T 1991-10-07 1992-10-06 Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein DK0786255T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77270591A 1991-10-07 1991-10-07
US85070692A 1992-03-12 1992-03-12

Publications (1)

Publication Number Publication Date
DK0786255T3 true DK0786255T3 (da) 2002-04-15

Family

ID=27118640

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96117245T DK0786255T3 (da) 1991-10-07 1992-10-06 Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein

Country Status (9)

Country Link
EP (2) EP0786255B1 (fr)
JP (2) JPH07502495A (fr)
AT (1) ATE210454T1 (fr)
AU (1) AU678141B2 (fr)
CA (1) CA2120731C (fr)
DE (1) DE69232295T2 (fr)
DK (1) DK0786255T3 (fr)
ES (1) ES2169783T3 (fr)
WO (1) WO1993006852A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607332B1 (fr) * 1991-10-07 1997-12-17 Biogen, Inc. Procede prophylactique ou therapeutique de maladies de la peau causees par des cellules presentant des antigenes au moyen d'inhibiteurs de l'interaction entre cd2 et lfa-3
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0749323B1 (fr) * 1994-03-08 2000-11-29 Dana-Farber Cancer Institute Procedes de modulation de l'anergie des cellules t
AU2006202939B2 (en) * 1994-03-08 2008-11-20 Dana-Farber Cancer Institute, Inc. Methods of modulating T cell unresponsiveness
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
HUP0103563A3 (en) * 1998-08-31 2004-04-28 Biogen Idec Ma Inc Cambridge Method of modulating memory effector t-cells and compositions
SI1109570T1 (sl) * 1998-08-31 2006-04-30 Biogen Idec Inc Modulacija spominskih efektorskih T-celic z vezavnim sredstvom CD2
AU2980900A (en) 1999-02-04 2000-08-25 General Hospital Corporation, The Methods for human allografting
CA2454618C (fr) 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
WO2005115436A1 (fr) 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
EP3774863A1 (fr) * 2018-03-29 2021-02-17 Pfizer Inc Variants de lfa3, compositions et utilisations associées

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260880A3 (fr) * 1986-09-11 1990-03-07 Dana-Farber Cancer Institute, Inc. Méthode de déclenchement de la cytotoxicité
CA1326940C (fr) * 1987-02-26 1994-02-08 Michael Dustin Purification du lfa-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990008187A1 (fr) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Proteine cd2 soluble a deux domaines
WO1991011194A1 (fr) * 1990-01-24 1991-08-08 Biogen, Inc. Lfa-3 utilise comme adjuvant de vaccins
US5547853A (en) * 1991-03-12 1996-08-20 Biogen, Inc. CD2-binding domain of lymphocyte function associated antigen 3
EP0607332B1 (fr) * 1991-10-07 1997-12-17 Biogen, Inc. Procede prophylactique ou therapeutique de maladies de la peau causees par des cellules presentant des antigenes au moyen d'inhibiteurs de l'interaction entre cd2 et lfa-3

Also Published As

Publication number Publication date
JPH07502495A (ja) 1995-03-16
EP0607353A1 (fr) 1994-07-27
ATE210454T1 (de) 2001-12-15
WO1993006852A2 (fr) 1993-04-15
AU2889192A (en) 1993-05-03
EP0786255A1 (fr) 1997-07-30
JP2003128579A (ja) 2003-05-08
CA2120731A1 (fr) 1993-04-15
DE69232295T2 (de) 2002-07-18
ES2169783T3 (es) 2002-07-16
WO1993006852A3 (fr) 1993-07-22
CA2120731C (fr) 2008-08-19
AU678141B2 (en) 1997-05-22
EP0786255B1 (fr) 2001-12-12
DE69232295D1 (de) 2002-01-24

Similar Documents

Publication Publication Date Title
DK0786255T3 (da) Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DK0621786T3 (da) Induceret tolerance over for xenotransplantater
FI963424A0 (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
DK651088D0 (da) Konjugater af laegemidler og monoklonale antistoffer
DK0751781T3 (da) Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
DK0476044T3 (da) Anvendelse af IGF1 eller IGF2 til fremstilling af et lægemiddeltil behandling af amyotrof, lateral sklerose
DE69115441D1 (de) Injektionsspritze
EP0330227A3 (fr) Dérivés de T-4 solubles
DE69010206D1 (de) Stabilisierte protein- oder peptidkonjugate.
IT8819961A0 (it) Dispositivo protesico composito modulare di gamba e piede.
RU99109594A (ru) Способы и композиции для иммуномодуляции
DK0656061T3 (da) Hidtil ukendte glycoformer af genopløselig komplementreceptor type 1
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
DK0546076T3 (da) Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
DK0601052T3 (da) Terapeutisk fremgangsmåde til behandling af IDDM
AU3757789A (en) Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates
NO892015L (no) Fremgangsmaate for fremstilling av et legemiddel.
PT89224A (pt) Processo para a preparacao de peptidos para o bloqueamento da actividade do pai-1 no sangue humano e sua utilizacao na preparacao de anticorpos
AU7178298A (en) Magnetic resonance blood pool agents
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
MD1612G2 (ro) Metodă de tratament al pielonefritei cronice la gravide